RNA Therapeutics Conference and Focus Day

SMi Group 19 - 20 February 2020, London, UK.
The field of RNA therapeutics is rapidly expanding, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

The event will focus on the latest research and developments on delivery system technologies that aim to tackle more difficult targets within the human body. This overarching topic warrants high focus and therefore, for the first time in the series, introduce a focus day on Oligonucletide Delivery Systems. The main conference will focus on current developments in the area of mRNA therapeutics in immunotherapy and vaccination.

New for 2020: RNA Therapeutics Focus Day - Oligonucleotide Delivery Systems

18 February 2020, London, UK.
Introducing the only RNA therapeutics conference to hold a full day exploring alternatives to oligonucleotide delivery systems. The global antisense and RNA therapeutics market is expected to expand at a compound annual growth rate (CAGR) of 8.6% between 2019 and 2025, projected to reach $1.81 billion, this focus day will assess the growing need for research and development of novel delivery approaches to expand the current delivery methods in today's market.

How will you benefit?

  • Discuss the innovations in oligonucleotide delivery systems
  • Explore the latest developments in RNA delivery agents and RNA-based therapeutics
  • Learn from case studies on clinical developments with leading RNA therapeutics companies and regulatory bodies
  • Revisit the challenges for clinical translation of RNA-based therapeutics
  • Evaluate the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing
  • Gain an expert view on new and upcoming regulatory updates and industry implications

Network and learn from leading professionals such as:

Chair for 2020

Heinrich Haas, VP RNA Formulation and Drug Delivery,BioNTech

Featured speakers include

  • Shalini Andersson, Chief Scientist New Therapeutic Modalities,AstraZeneca
  • Christian Plank, CTO, Ethris
  • Steve Pascolo, Founder and CEO, Miescher Pharma
  • Kirsty Wydenbach, Deputy Unit Manager, Clinical Trials Unit, MhRA
  • Steven Powell, CEO, eTheRNA
  • Simon Newman, CSO, Nanogenics
  • Christiane Niederlaender, Director, AMBR Consulting and Formerly,
  • Quality Assessor, Biologicals, MhRA
  • Klaus Giese, CEO, Pantherna Therapeutics
  • David Blakey, CSO, MiNA Therapeutics
  • Jeffrey Ulmer, Head Preclinical R&D, GSK

For more information and to register, please visit:
http://www.therapeutics-rna.com/worldpharmanews

Early-Bird Rates

Register by 31st October to save £400 Register by 29th November to save £200 Register by 29th December to save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...